PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Clin Cancer Res. Author manuscript; available in PMC 2010 December 15.
Published in final edited form as:
PMCID: PMC2805170
NIHMSID: NIHMS150147

Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma

Abstract

Purpose

Activation of the PI3K-AKT pathway has been implicated in melanoma based primarily on the prevalence of mutations in PTEN and NRAS. To improve our understanding of the regulation and clinical significance of the PI3K-AKT pathway in melanoma, we quantitatively measured the levels of phosphorylated AKT (P-AKT), its substrate GSK3α/β, and its negative regulator PTEN in clinical metastases. Results were compared to mutational status, clinical outcomes, and sites of metastasis.

Experimental Design

DNA and protein were isolated from dissected frozen melanoma metastases (n=96). Activating mutations of BRAF, NRAS, AKT, PIK3CA, and KIT were detected by mass-spectroscopy genotyping. P-AKT (Ser473 and Thr308), P-GSK3α/β, and PTEN protein expression were measured by reverse phase protein array (RPPA). A panel of human melanoma cells lines (n=58) was analyzed for comparison.

Results

BRAF-mutant tumors had higher levels of P-AKT-Ser473 (P=.01), P-AKT-Thr308 (P=.002), and P-GSK3α/β (P=.08) than NRAS-mutant tumors. Analysis of individual tumors demonstrated that almost all tumors with elevated P-AKT had low PTEN levels; NRAS-mutant tumors had normal PTEN and lower P-AKT. Similar results were observed in melanoma cell lines. Stage III melanoma patients did not differ in overall survival based on activation status of the PI3K-AKT pathway. Brain metastases had significantly higher P-AKT and lower PTEN than lung or liver metastases.

Conclusions

Quantitative interrogation of the PI3K-AKT pathway in melanoma reveals unexpected significant differences in AKT activation by NRAS mutation and PTEN loss, and hyperactivation of AKT in brain metastases. These findings have implications for the rational development of targeted therapy for this disease.

Keywords: melanoma, signal transduction, AKT, BRAF, NRAS

Introduction

Melanoma is the most aggressive form of skin cancer. It is estimated that 68,720 patients will be diagnosed with melanoma, and 8,650 patients will die of this disease, in 2009 (1). Clinical trials of chemotherapy, immunotherapy, and biochemotherapy have failed to significantly improve outcomes in melanoma (2). Thus, new therapeutic approaches are needed.

Somatic mutations in BRAF, a serine-threonine kinase that is a component of the RAS-RAF-MAPK signaling pathway, are detected in ~50% of melanomas (3). These mutations result in constitutive activation of BRAF, with resultant activation of MAPK in vitro (4). Unfortunately, the pan-RAF inhibitor sorafenib failed to improve outcomes in patients with metastatic melanoma (5). It is possible that the lack of efficacy was due to insufficient inhibition of the RAS-RAF-MAPK pathway, as is suggested by the recent promising, albeit preliminary, results with the more potent, selective inhibitor of mutant BRAF, PLX4032 (6). However, there is also evidence that activating mutations in BRAF alone cannot fully explain the pathogenesis of this disease. For example, although benign nevi have no malignant potential, they harbor BRAF mutations at a rate similar to melanomas (7, 8). Mutant BRAF also failed to transform melanocytes without additional genetic lesions (9, 10). Thus, other molecules or pathways likely complement the activation of the RAS-RAF-MAPK signaling pathway in melanoma. An improved understanding of these pathways may lead to more effective therapeutic strategies.

One candidate pathway is the PI3K-AKT cascade. NRAS, which is located upstream of BRAF in the RAS-RAF-MAPK signaling cascade, is mutated in ~15% of melanomas (3). Similar to mutant BRAF, mutant NRAS activates the RAS-RAF-MAPK cascade. In contrast to BRAF, NRAS can also activate PI3K (11). Activation of the PI3K-AKT pathway has also been implicated in melanoma by loss-of-function mutations in PTEN, which have been detected in 10-30% of melanomas (12, 13). As PTEN is a lipid phosphatase that antagonizes PI3K activity, and thus inhibits PI3K-AKT signaling, loss of PTEN results in activation of the PI3K-AKT pathway in several tumor types, including melanoma (14, 15). PTEN mutations are often observed in melanomas harboring BRAF mutations, whereas NRAS mutations do not occur with either BRAF or PTEN mutations (16, 17). Thus, the combination of BRAF and PTEN mutations may mimic the effect of mutant NRAS. In addition, ~5% of melanomas have activating mutations in PIK3CA, the catalytic subunit of the most commonly expressed form of PI3K, AKT1, or AKT3 (18-20).

While multiple genetic events implicate the PI3K-AKT pathway in melanoma, few studies have directly assessed the activation status of this pathway in metastases, and have generally been performed using nonquantitative methods (21-24). Quantitative assessment of protein expression facilitates objective comparisons between molecular and clinical characteristics and mathematical approaches to assess interactions. Direct, quantitative approaches may be particularly relevant for assessing the role of PTEN in melanoma, as PTEN expression can be lost in the absence of detectable mutations, and its functional status is more accurately assessed by quantitative measures of expression than by immunohistochemical (IHC) analysis (13, 25-27). Reverse-phase protein arrays (RPPA) are a powerful tool that allow for quantitative analysis of protein expression and activation using small amounts of protein (28). Previously, we used RPPA to analyze the activation of the PI3K-AKT pathway in breast cancer (29). That study demonstrated an expected inverse relationship between PTEN protein levels and phosphorylated (activated) AKT (P-AKT) levels in breast cancer but a surprising lack of elevated P-AKT in most tumors with PIK3CA mutations. The non-equivalence of different mutations in the PI3K-AKT pathway is also supported by concurrent mutations of PIK3CA and PTEN in endometrial cancers, and concurrent RAS and PIK3CA mutations in colon cancers (30, 31). Thus, there is a strong rationale for quantitatively analyzing the activation status of AKT in melanoma, particularly as numerous agents that target this pathway are in clinical development (32).

In this study, we used RPPA to perform a quantitative analysis of AKT activation in dissected, well-annotated melanoma clinical specimens and cell lines. We analyzed associations between AKT activation and mutational status, clinical outcomes, and anatomic sites of metastasis. Surprisingly, we observed significantly greater activation of AKT with loss of PTEN expression than with NRAS mutation in both tumors and cell lines. Our data also implicates activation of AKT in melanoma brain metastases.

Experimental Design

Clinical specimens

OCT-embedded frozen clinical specimens were obtained from the Melanoma Informatics, Tissue Resource, and Pathology Core, and the Central Nervous System Tissue Bank at The University of Texas M. D. Anderson Cancer Center under Institutional Review Board–approved protocols. Hematoxylin and eosin (H&E)-stained slides were reviewed by an experienced dermatopathologist or neuropathologist (VGP, AJFL, or KA) to identify regions that contained >70% tumor cells and to exclude areas of necrosis, fibrosis, or hemorrhage within the tumor specimens. These slides were used as a guide to macrodissect the OCT blocks and isolate tumor-enriched regions for further studies. 10-20 μm tumor shears were prepared by cryostat from the isolated regions at −20°C and stored at −80°C for molecular studies. An additional H&E-stained slide was then prepared to confirm >70% tumor content after processing.

Cell lines

A full list of the cell lines used is summarized in Table S1. Short tandem repeat (STR) DNA fingerprinting analysis was performed on all cell lines using the Applied Biosystems AmpFSTR kit to confirm their identity. For lysate generation, cells were grown at 37°C with 5% CO2 in RPMI media supplemented with 5% fetal calf serum (FCS). When cells reached approximately 70% confluence, the media was removed and replaced with fresh RPMI with either 5% (“serum-replete”) or 0% (“serum-starved”) FCS. Cells were harvested for proteins 24 h later.

Reverse phase protein array analysis

Proteins were isolated from tumor shears and cell lines, and RPPA analysis was performed as previously described (29, 33). RPPA was performed using a total of 53 antibodies (Table S2); this study includes the results for antibodies against P-AKT-Ser473, P-AKT-Thr308, total AKT, PTEN, P-GSK3α/β-Ser21/Ser9 (Cell Signaling), total GSK3α/β (Santa Cruz Biotechnology), and KIT (Epitomics). Prior antibody testing confirmed the specificity of each antibody, and direct correlation between RPPA and Western blotting results (data not shown). A logarithmic value was generated, reflecting the quantitation of the relative amount of each protein in each sample (34). Differences in relative protein loading were determined by the median protein expression for each sample across all measured proteins using data that had been normalized to the median value of each protein. The raw data were then divided by the relative-loading factor to determine load-corrected values. Logarithmic values for each protein were mean-centered to facilitate concurrent comparisons of different proteins.

Western blot analyses

Western blot analyses were performed using standard methods (29). Membranes were probed with antibodies against total AKT, P-AKT-Ser473, P-AKT-Thr308, PTEN (Cell Signaling); AKT1, AKT 3 (Upstate Biotechnology); AKT2, and ERK2 (Santa Cruz Biotechnology).

Immunohistochemical analysis

IHC analysis was performed on 5-μm sections cut from formalin-fixed, paraffin-embedded tumor blocks (35). Slides were probed with an antibody against P-AKT-Ser473 (1:25 dilution; Cell Signaling). When indicated, IHC analysis to confirm the presence of melanoma was performed with a cocktail of antibodies (“Pan-mel”) against three antigens present in melanoma (HMB45, Mart1, anti-tyrosinase) as described previously (36). All IHC analyses were reviewed by an experienced dermatopathologist (AJL).

Mutation detection

Extraction of DNA from tumors and cell lines was performed as previously described (20). Activating mutations in BRAF, NRAS, AKT1, AKT2, AKT3, PIK3CA, and KIT (Table S3) were detected by mass-spectroscopy genotyping (20, 37).

Statistical analysis

Student’s t-test was used to compare protein expression levels between groups. Protein-protein correlation coefficients were determined by the Pearson correlation method, and the significance of the interactions was determined by the t-statistic using R software1. Unsupervised hierarchical clustering of mean-centered protein expression values was performed using Cluster 2.1 and Treeview software2. Overall survival (OS) was defined as either the time between surgical accession (date the analyzed specimen was harvested) and last follow-up or death or the time between the original date of melanoma diagnosis and last follow-up date or death. Central nervous system (CNS) disease-free survival was defined as the time between the date of surgical accession and the date of diagnosis of CNS involvement, censored to the last negative CNS imaging. The Kaplan-Meier product-limit method was used to generate survival curves, and the log-rank test was used to assess the difference in survival rates between groups. Univariate and multivariate Cox proportional hazards regression models were used to assess the hazards ratios. All computations were performed using SAS (SAS Institute) and S-plus version 8.0 (Insightful Corp) software.

Results

Technical assessment of reverse phase protein array analysis of melanoma samples

Tumor-enriched isolates from 96 frozen melanoma samples, including 6 cutaneous tumors, 70 regional metastases (55 lymph node, 15 soft tissue), and 20 distant metastases (10 brain, 5 liver, and 5 lung), were analyzed by RPPA. We found a positive correlation between P-AKT-Ser473 levels and levels of its known substrates P-GSK3α/β (r=.675; P<.001) and P-TSC2 (r=.549; P<.001). Levels of PTEN, a negative regulator of AKT activation, negatively correlated with levels of P-AKT-Ser473 (r=−.574; P<.001) and P-AKT-Thr308 (r=−.634; P<.001). Similar protein-protein correlations were observed for P-AKT-Ser473 levels in proteins isolated from melanoma cell lines grown in vitro (P-GSK3α/β, r=.46; P-TSC2, r=.63; PTEN, r=−.552; P<.001 for each).

To test the technical reproducibility of the analysis, eight lysates were printed on separate regions of each RPPA slide, and we determined the Pearson correlation coefficients for levels of P-AKT-Ser473, P-AKT-Thr308, P-GSK3α/β, P-TSC2, and PTEN for the matched samples (average r=.992). In addition, cell lysates were prepared at different times using independent shears from 10 tumors (r=.851 for pairs). Taken together, these results confirm that the phosphoproteins of interest were maintained during the preparation of samples and that the RPPA results are reproducible.

AKT activation in human melanoma tumors and its correlation with activating mutations

Tumors were assessed for the presence of activating BRAF, NRAS, AKT, PIK3CA, and KIT mutations by mass spectroscopy-based genotyping (Table 1). Thirty-nine (40.6%) of the tumors harbored a BRAF mutation, 18 (18.8%) harbored an NRAS mutation, and 37 (38.5%) were wild-type for BRAF and NRAS. One tumor with an activating BRAF mutation also had an AKT1-E17K mutation, while another BRAF-mutant tumor had an AKT3-E17K mutation. No PIK3CA mutations were detected. Two tumors had KIT mutations (K462E and K560D); neither tumor had a concurrent BRAF or NRAS mutation. Two tumors with indeterminate results were classified as “unknown mutation” and were excluded from the subsequent analysis.

Table 1
Mutations in clinical melanoma specimens.

To determine the relationship between mutation status and AKT activation, we measured the levels of P-AKT-Ser473 and P-AKT-Thr308 in the tumors by RPPA (Fig. 1A). Surprisingly, the BRAF-mutant tumors had significantly higher levels of P-AKT-Ser473 (P=.01) and P-AKT-Thr308 (P=.002) than NRAS-mutant tumors. Consistent with increased AKT activity, BRAF-mutant tumors also showed a trend toward higher levels of P-GSK3α/β (P=.08) than NRAS-mutant tumors. There was no significant difference in the levels of total AKT or GSK3α/β between BRAF- and NRAS-mutant tumors (Fig. S1). BRAF-mutant tumors also had significantly lower levels of PTEN than NRAS-mutant tumors (P=.005; Fig. 1).

Figure 1
RPPA analysis of AKT activation in melanoma clinical specimens and correlation with activating mutations. A, Average expression levels of P-AKT-Ser473 (blue), P-AKT-Thr308 (red), P-GSK3α/β (yellow), and PTEN (green) in BRAF-mutant or NRAS-mutant ...

To further evaluate AKT activation according to mutation status, we assessed relative levels of P-AKT in the individual tumors (Fig. 1B to D). In these figures, each tumor was colored proportionally to the level of PTEN expression. While P-AKT levels for many of the BRAF-mutant tumors were comparable to levels in NRAS-mutant and most wild-type tumors (Fig. 1B and C), a subset of the BRAF-mutant tumors had markedly elevated P-AKT; all of these tumors with markedly elevated P-AKT had low PTEN. In contrast, all NRAS-mutant tumors had relatively high PTEN and low P-AKT levels. Some wild-type tumors had elevated P-AKT; of these, almost all had relatively low PTEN. For the two tumors with KIT mutations, we observed high P-AKT and P-GSK3α/β levels in the tumor with the K462E mutation, which also had high KIT expression (Fig. S2). Interestingly, the two tumors with AKT mutations had low levels of P-AKT and P-GSK3α/β. While P-GSK3α/β was elevated in most tumors with low PTEN, relatively high P-GSK3α/β levels were also noted in some tumors that did not have low PTEN levels. This may be due to the activity of kinases other than AKT that can phosphorylate GSK3α/β, including P90 RSK, P70 S6K, PKC isoforms, and PKA (38).

We performed IHC analyses of two tumors with high and low P-AKT-Ser473 levels, as assessed by RPPA, using formalin-fixed paraffin-embedded specimens that were harvested during the same surgery as the frozen tumors analyzed by RPPA. The tumor with high levels of P-AKT-Ser473 (Fig. 2A) demonstrated homogenous, strong staining for P-AKT, whereas the tumor with low P-AKT-Ser473 (Fig. 2B) had homogenously weaker staining. Normal lymphocytes demonstrated almost no staining for P-AKT.

Figure 2
Comparison of RPPA results with IHC analysis of P-AKT. IHC staining for P-AKT-Ser473 on formalin-fixed, paraffin-embedded tissues from melanoma lymph node metastases. Black circle outlines the tumor deposit in each lymph node. A, Tumor with high P-AKT-Ser473 ...

AKT activation in melanoma cell lines

We extended our analysis to a panel of 58 human melanoma cell lines, which offers the theoretical advantage of allowing examination of homogenous populations of tumor cells and the ability to finely control conditions during protein harvest. Forty-six (79.3%) cell lines had BRAF mutations, eight (13.8%) had NRAS mutations, and four (6.9%) had no detectable mutations in either BRAF or NRAS (Table S1). Two cell lines with activating BRAF mutations had concurrent AKT3-E17K mutations and one wild-type cell line had a KIT-L576P mutation. BRAF-mutant cell lines had higher P-AKT-Ser473 (P=.01, serum-replete; P=.03, serum-starved) and P-AKT-Thr308 (P=.01 and P=.07) levels than NRAS-mutant cell lines (Fig. 3A and B). The average P-GSK3α/β level was also higher in the BRAF-mutant cell lines, but this difference was not statistically significant (data not shown). As observed in the tumors, most cell lines with elevated P-AKT also had low PTEN expression. Western blotting of independent cell lysates generated under serum-replete conditions was performed on representative cell lines, and the results confirmed the relative differences in P-AKT levels between cell lines with PTEN loss and those with NRAS mutations (Fig. 3C). Elevated P-AKT was not observed in one of the cell lines with loss of PTEN (WM1552). When probed for the individual isoforms of AKT(AKT1, AKT2, AKT3), this cell line had low levels of AKT3; in contrast, the other cell lines with PTEN loss and elevated P-AKT had high levels of AKT3. This correlation between reduced P-AKT levels and a specific reduction in AKT3 expression is consistent with previous reports suggesting that this AKT isoform may be critical in melanoma (39, 40).

Figure 3
AKT activation in human melanoma cell lines. A, RPPA analysis of levels of P-AKT-Ser473 in cells following serum starvation for 24 h. Cells are grouped on the basis of mutations in BRAF and NRAS. Cell lines with AKT3(An external file that holds a picture, illustration, etc.
Object name is nihms-150147-ig0006.jpg) and KIT([big up triangle, open]) mutations are ...

AKT activation and clinical outcome

To assess the prognostic significance of the AKT pathway in melanoma, we examined clinical outcomes in patients with regional metastases (i.e., regional lymph node or soft-tissue). Fourteen patients who had already developed distant metastases prior to the collection of regional metastatic specimens were excluded from the survival analyses.

By univariate analysis, overall survival did not vary according to the levels of P-AKT-Ser473, P-AKT-Thr308, or PTEN, using each protein as a continuous variable (data not shown). To assess the prognostic significance of the coordinate regulation of these proteins, we dichotomized patients as “P-AKT High/PTEN Low” or “P-AKT Low/PTEN High” based on clustering analysis of the RPPA results for these proteins (Fig. 4A). There were no significant differences in overall survival between these groups, regardless of whether survival was calculated from the date of surgery and tumor specimen acquisition (Fig. 4B) or initial melanoma diagnosis (Fig. 4C).

Figure 4
AKT activation and clinical outcomes. A, Unsupervised hierarchical clustering of 56 regional(lymph node, soft tissue) metastases based on the expression levels of P-AKT-Ser473, P-AKT-Thr308, and PTEN. For comparative analyses, tumors in the upper cluster ...

Potential impact of anatomic sites of melanoma on AKT activation

As an exploratory study of the impact of anatomic site of involvement on signaling pathways, we analyzed the small set of resected distant metastases included in the analysis of mutational status versus AKT activation. Overall there was no significant difference in P-AKT levels between the distant metastases (brain, liver, and lung; n=20) and the regional metastases (lymph node and soft tissue; n=70; data not shown). However, among the distant metastases there was a significant difference in the activation of AKT among the different anatomic sites of involvement (Fig. 5A). Compared to liver and lung metastases, brain metastases demonstrated higher levels of P-AKT-Ser473 (P=.002 versus liver; P=0.008 versus lung), P-AKT-Thr308 (P=.04 and P=.01), and P-GSK3α/β (P=.10 and P=.003). The brain metastases also had lower levels of PTEN, although this difference was statistically significant only when compared to lung metastases (P=.05). Scatter plots of the distant metastases (Fig. 5B, C) demonstrated that the lung and liver metastases had relatively homogenous, low levels of P-AKT; only one had low PTEN expression. In contrast, 60% of the brain metastases had low PTEN and elevated P-AKT levels. The brain metastases with elevated P-AKT included one tumor with a KIT-K462E mutation, three tumors with BRAF mutations, and two tumors with no known mutations. IHC analysis of representative FFPE tissue from a brain metastasis with elevated P-AKT by RPPA analysis demonstrated robust staining for P-AKT in the tumor and a lack of staining in normal brain tissue, supporting that this difference is unlikely to be due to non-tumor elements in the specimens (Fig. S3). In contrast, a FFPE lung metastasis from the same patient did not express P-AKT in the tumor or stroma by IHC (Fig. S3). Among the patients with regional metastases, there was a trend, although not statistically significant, towards an increased risk of CNS metastasis for patients with the “P-AKT High/PTEN Low” signature as compared with patients with the “P-AKT Low/PTEN High” signature (log-rank P=.18; Fig. S4).

Figure 5
AKT activation by metastatic site. A, Average expression levels of P-AKT-Ser473 (blue), P-AKT-Thr308 (red), P-GSK3α/β (yellow), and PTEN (green) in melanoma metastases resected from the brain, liver, and lung, as determined by RPPA. *, ...

Discussion

Activation of AKT has been implicated in melanoma by the prevalence of NRAS and PTEN mutations and by immunohistochemical studies. We have quantitatively measured phosphorylated AKT in melanoma metastases in order to better define its activation status in patients with systemic disease, and to explore its relationship with mutations and clinical factors.

NRAS mutations, which occur in ~15% of melanomas, do not occur with either BRAF or PTEN mutations (16, 17, 41). This lack of redundancy suggests that NRAS mutations are sufficient to activate both the PI3K and the MAPK pathways. Consistent with the reported pattern of PTEN mutations, we found very low levels of PTEN in a subset of the BRAF-mutant tumors and in some wild-type tumors, but relatively high levels of PTEN in all NRAS-mutant tumors. Moreover, almost all tumors with low PTEN had high P-AKT. Surprisingly, RPPA analysis demonstrated that NRAS-mutant tumors had P-AKT levels that were much lower than those in tumors with PTEN loss. In fact, P-AKT levels in NRAS-mutant tumors were comparable to those in tumors with no identified activating mutation. The validity of this finding is supported by the nearly identical results we observed in melanoma cell lines.

Although multiple models have implicated PI3K as a critical mediator of mutant NRAS-mediated signaling, there is limited direct evidence that NRAS mutations activate AKT in melanoma. While the introduction of mutant NRAS into human melanoma cells is associated with acutely elevated P-AKT levels (42), our data suggest that melanomas develop compensatory changes over time that abrogate this effect. Our findings are consistent with a recent IHC study that found no significant increase in P-AKT levels in NRAS-mutant primary melanomas as compared with BRAF-mutant or wild-type primary melanomas (43). PTEN genetic status or protein expression was not included in that study. Interestingly, we previously observed a similar apparent discrepancy in the effects of PI3K mutations. In contrast to the elevated P-AKT levels seen with acute expression of mutant PI3K, tumors and cell lines with somatic mutations in PI3K did not generally have elevated P-AKT (29, 44, 45). The lack of elevated P-AKT in melanomas with NRAS mutations does not preclude the possible contribution of other PI3K-regulated proteins in mediating the effects of mutant-NRAS in melanoma. However, our data suggests that treatments with selective efficacy in the setting of AKT hyperactivation may be most appropriate for melanomas with PTEN loss and not for melanomas with NRAS mutations (44, 46).

In this study, neither P-AKT nor PTEN expression levels were associated with overall survival in patients with regional melanoma metastases. Recent studies that examined the relationship of P-AKT levels to clinical outcome in melanoma have focused mainly on primary tumors (21, 43). In one immunohistochemistry-based study, the authors concluded that the presence of “strong” P-AKT was associated with poor overall survival (21). However, most of the observed differences in P-AKT levels and overall survival were related to patients with relatively thin primary tumors (tumor thickness < 1.5 mm). Another study reported that lack of P-AKT actually correlated with worse outcomes in a small group of patients with primary tumors (43).

CNS involvement is a common manifestation of metastatic melanoma and is the cause of death in the majority of affected patients (47, 48). Preclinical models have previously implicated several proteins in the development of melanoma brain metastases, including TGF-β2 and STAT3 (49, 50). However, these studies did not include a direct examination of distant metastases from different sites from patients. Such studies are generally challenging because distant parenchymal metastases are usually treated with systemic therapies, not surgical resection. In the small panel of distant metastases included in this study, we found that brain metastases had significantly higher P-AKT and lower PTEN expression than distant metastases from the lung and liver. While it is possible that the increased P-AKT in brain metastases results from increased efficiency of circulating melanoma cells with activation of AKT to form metastases at this site in the body, we did not detect a significant difference in CNS involvement among Stage III patients with High P-AKT/Low PTEN (Fig. S4). These findings support the need for larger studies of distant metastases, including matched metastases from multiple sites in the same patient, to address the possibility of site-specific activation of different pathways. Such findings would support the need for the exploration of site-specific therapeutic approaches.

In summary, we have used RPPA to quantitatively analyze the activation of AKT in melanoma metastases and cell lines. This analysis was performed with a relatively large number of carefully dissected and well-annotated clinical specimens and included analyses of reproducibility, known substrates and regulators of AKT, and confirmatory western blot and IHC analyses. These findings have implications for the rational application of agents targeting the PI3K-AKT pathway in this disease. Importantly, this study demonstrates the tremendous potential of prospective collection of well-annotated and carefully processed biospecimens and RPPA for the study of melanoma. When integrated with relevant molecular, clinical, and pathologic information, such studies have the potential to improve our understanding of the molecular pathogenesis of metastatic melanoma and lead to improved therapeutic approaches for this highly aggressive and poorly understood disease.

Translational Relevance

Activation of the PI3K-AKT pathway has been implicated in multiple tumor types, and inhibitors targeting this pathway are currently undergoing clinical testing. We quantitatively measured AKT activation in well-annotated melanoma clinical metastases and cell lines, and performed an integrated proteomic analysis with molecular and clinical endpoints. As expected, AKT activation was increased in the setting of PTEN loss. Surprisingly, AKT activation was not increased in NRAS-mutant tumors or cell lines. Furthermore, AKT activation differed among tumors from different distant metastatic sites. These findings challenge the presumed activation of AKT by NRAS mutations, and suggest the possibility of site-specific activation of signaling pathways in this disease.

Supplementary Material

Acknowledgments

Supported in part by The University of Texas M. D. Anderson Cancer Center Melanoma SPORE and the Melanoma Informatics, Tissue Resource, and Pathology Core to MAD, AJL, JEG, and VGP (P50 CA93459); Carol Codgell Courtney Fellowship to SEW and MAD; American Society of Clinical Oncology Young Investigator Award to MAD; Institutional Physician-Scientist Award to AJL; Grossman Family Foundation to JEG; The DNA Sequencing Core Facility and the Reverse Phase Protein Array Core Facility are supported by an NCI Cancer Center Support Grant (CA-16672).

References

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009 caac.20006. [PubMed]
2. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med. 2004;351:998–1012. [PubMed]
3. Hocker T, Tsao H. Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. Hum Mutat. 2007;28:578–88. [PubMed]
4. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–54. [PubMed]
5. Eisen T, Ahmad T, Flaherty KT, et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer. 2006;95:581–6. [PMC free article] [PubMed]
6. Flaherty KT, Puzanov J, Sosman J, et al. Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol. 2009;27:9000.
7. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet. 2003;33:19–20. [PubMed]
8. Yazdi AS, Palmedo G, Flaig MJ, et al. Mutations of the BRAF gene in benign and malignant melanocytic lesions. J Invest Dermatol. 2003;121:1160–2. [PubMed]
9. Michaloglou C, Vredeveld LCW, Soengas MS, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature. 2005;436:720–4. [PubMed]
10. Patton EE, Widlund HR, Kutok JL, et al. BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol. 2005;15:249–54. [PubMed]
11. Rodriguez-Viciana P, Warne PH, Dhand R, et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature. 1994;370:527–32. [PubMed]
12. Tsao H, Zhang X, Benoit E, Haluska FG. Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene. 1998;16:3397–402. [PubMed]
13. Zhou XP, Gimm O, Hampel H, Niemann T, Walker MJ, Eng C. Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am J Pathol. 2000;157:1123–8. [PubMed]
14. Davies MA, Lu Y, Sano T, et al. Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis. Cancer Res. 1998;58:5285–90. [PubMed]
15. Stahl JM, Cheung M, Sharma A, Trivedi NR, Shanmugam S, Robertson GP. Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res. 2003;63:2881–90. [PubMed]
16. Goel VK, Lazar AJ, Warneke CL, Redston MS, Haluska FG. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J Invest Dermatol. 2006;126:154–60. [PubMed]
17. Tsao H, Goel V, Wu H, Yang G, Haluska FG. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol. 2004;122:337–41. [PMC free article] [PubMed]
18. Curtin JA, Stark MS, Pinkel D, Hayward NK, Bastian BC. PI3-kinase subunits are infrequent somatic targets in melanoma. J Invest Dermatol. 2006;126:1660–3. [PubMed]
19. Omholt K, Krockel D, Ringborg U, Hansson J. Mutations of PIK3CA are rare in cutaneous melanoma. Melanoma Res. 2006;16:197–200. [PubMed]
20. Davies MA, Stemke-Hale K, Tellez C, et al. A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer. 2008;99:1265–8. [PMC free article] [PubMed]
21. Dai DL, Martinka M, Li G. Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. J Clin Oncol. 2005;23:1473–82. [PubMed]
22. Dhawan P, Singh AB, Ellis DL, Richmond A. Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression. Cancer Res. 2002;62:7335–42. [PubMed]
23. Li G, Kalabis J, Xu X, et al. Reciprocal regulation of MelCAM and AKT in human melanoma. Oncogene. 2003;22:6891–9. [PubMed]
24. Slipicevic A, Holm R, Nguyen MTP, Bøhler PJ, Davidson B, Flørenes VA. Expression of Activated Akt and PTEN in Malignant Melanomas. American Journal of Clinical Pathology. 2005;124:528–36. [PubMed]
25. Mirmohammadsadegh A, Marini A, Nambiar S, et al. Epigenetic Silencing of the PTEN Gene in Melanoma. Cancer Res. 2006;66:6546–52. [PubMed]
26. Yang H, Kong W, He L, et al. MicroRNA Expression Profiling in Human Ovarian Cancer: miR-214 Induces Cell Survival and Cisplatin Resistance by Targeting PTEN. Cancer Res. 2008;68:425–33. [PubMed]
27. Saal LH, Johansson P, Holm K, et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A. 2007;104:7564–9. [PubMed]
28. Liotta LA, Espina V, Mehta AI, et al. Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell. 2003;3:317–25. [PubMed]
29. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 2008;68:6084–91. [PMC free article] [PubMed]
30. Oda K, Stokoe D, Taketani Y, McCormick F. High Frequency of Coexistent Mutations of PIK3CA and PTEN Genes in Endometrial Carcinoma. Cancer Res. 2005;65:10669–73. [PubMed]
31. Oda K, Okada J, Timmerman L, et al. PIK3CA Cooperates with Other Phosphatidylinositol 3′-Kinase Pathway Mutations to Effect Oncogenic Transformation. Cancer Res. 2008;68:8127–36. [PubMed]
32. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005;4:988–1004. [PubMed]
33. Hennessy BT, Lu Y, Poradosu E, et al. Pharmacodynamic markers of perifosine efficacy. Clin Cancer Res. 2007;13:7421–31. [PubMed]
34. Tibes R, Qiu Y, Lu Y, et al. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther. 2006;5:2512–21. [PubMed]
35. Ivan D, Niveiro M, Diwan AH, et al. Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, GleevecTM) Journal of Cutaneous Pathology. 2006;33:280–5. [PubMed]
36. Hoang MP, Prieto VG, Burchette JL, Shea CR. Recurrent melanocytic nevus: a histologic and immunohistochemical evaluation. J Cutan Pathol. 2001;28:400–6. [PubMed]
37. Thomas RK, Baker AC, Debiasi RM, et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007;39:347–51. [PubMed]
38. Grimes CA, Jope RS. The multifaceted roles of glycogen synthase kinase 3[beta] in cellular signaling. Progress in Neurobiology. 2001;65:391–426. [PubMed]
39. Stahl JM, Sharma A, Cheung M, et al. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res. 2004;64:7002–10. [PubMed]
40. Tran MA, Gowda R, Sharma A, et al. Targeting V600EB-Raf and Akt3 Using Nanoliposomal-Small Interfering RNA Inhibits Cutaneous Melanocytic Lesion Development. Cancer Res. 2008;68:7638–49. [PMC free article] [PubMed]
41. Tsao H, Zhang X, Fowlkes K, Haluska FG. Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res. 2000;60:1800–4. [PubMed]
42. Chudnovsky Y, Adams AE, Robbins PB, Lin Q, Khavari PA. Use of human tissue to assess the oncogenic activity of melanoma-associated mutations. Nat Genet. 2005;37:745–9. [PMC free article] [PubMed]
43. Jovanovic B, Krockel D, Linden D, Nilsson B, Egyhazi S, Hansson J. Lack of cytoplasmic ERK activation is an independent adverse prognostic factor in primary cutaneous melanoma. J Invest Dermatol. 2008;128:2696–704. [PubMed]
44. Vasudevan KM, Barbie DA, Davies MA, et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell. 2009;16:21–32. [PMC free article] [PubMed]
45. Zhao JJ, Liu Z, Wang L, Shin E, Loda MF, Roberts TM. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci U S A. 2005;102:18443–8. [PubMed]
46. Nogueira V, Park Y, Chen CC, et al. Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. Cancer Cell. 2008;14:458–70. [PMC free article] [PubMed]
47. Fife KM, Colman MH, Stevens GN, et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol. 2004;22:1293–300. [PubMed]
48. Sampson JH, Carter JH, Jr., Friedman AH, Seigler HF. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg. 1998;88:11–20. [PubMed]
49. Xie T-x, Huang F-J, Aldape KD, et al. Activation of Stat3 in Human Melanoma Promotes Brain Metastasis. Cancer Res. 2006;66:3188–96. [PubMed]
50. Zhang C, Zhang F, Tsan R, Fidler IJ. Transforming Growth Factor-{beta}2 Is a Molecular Determinant for Site-Specific Melanoma Metastasis in the Brain. Cancer Res. 2009;69:828–35. [PMC free article] [PubMed]